Patent Claims Archives

Moderna urges court to dismiss ongoing vaccine patent issues

Coronavirus Vaccines, Lipid Nanoparticles (LNPs), Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Nanoparticles, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, NIH, Patent Challenges, Patent Claims, Patents, Therapeutics

Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in the company’s COVID-19 vaccine, Spikevax.

May 9, 2022/by BioSpace

Apr 08, 2022 By Jazmine Colatriano, M.S. BioSpace Johnson & Johnson’s Janssen Pharmaceutical secured an arbitrary win regarding royalty decisions stemming from the licensing and marketing of daratumumab, an anti-CD38 monoclonal antibody treatment […]

April 8, 2022/by Christiane Truelove

Court Rules Against Amgen PCSK9 Patent Claims Against Sanofi and Regeneron

"Bad" LDL Cholesterol, Amgen, Blockbusters, Business, Cholesterol, Federal Courts, Patent Claims, PCSK9 inhibitors, Regeneron Pharmaceuticals, Rivalries, Sanofi, Therapeutics, U.S. Court Of Appeals

In a long-running court battle over PCSK9 antibodies, Amgen lost the company’s bid to uphold patent claims for the cholesterol drug Repatha against rival drug Praluent, developed by Sanofi and Regeneron.

February 12, 2021/by Andrew Humphreys

With Court Win, BMS and Pfizer Stave Off Generic Challengers to Eliquis

Blockbusters, Blood Clots, Blood Thinner, Business, Generics, Investors, Patent Claims, Patents, Strokes

A federal court upheld patent claims regarding Bristol Myers Squibb and Pfizer’s Eliquis, which blocks generic rivals from carving out a share of the market for at least six years.

August 6, 2020/by Andrew Humphreys